–FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia
–Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022
–LogicBio to present at ASGCT 2022 Annual Meeting
LEXINGTON, Mass., May 16, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.
"Earlier this month, we were pleased to announce that the FDA lifted the clinical hold on our LB-001 IND, allowing us to resume dosing of our SUNRISE trial," said Frederic Chereau, president and chief executive officer of LogicBio. "We are also excited to see the progression of our GeneRide® platform as well as advancements from our CMC team, including our proprietary mAAVRx™ system, which is a transfection process optimized to improve manufacturing yields and product quality. Finally, we continue to progress well with our Daiichi Sankyo and CANbridge collaborations."
Recent Business Highlights:
In May, LogicBio announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the company's LB-001 Investigational New Drug Application (IND), allowing patient dosing to resume in the Phase 1/2 SUNRISE trial in pediatric patients with methylmalonic acidemia. The company expects to dose the next patient in the SUNRISE trial in the third quarter of 2022. Following the lifting of the clinical hold, the company announced that it reinstated its previous guidance and expects to present interim clinical data from the SUNRISE trial by the end of the second quarter of 2022.
In May, LogicBio announced that it will present at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, to be held May 16-19, 2022. The two oral and two poster presentations highlight the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 models and optimized adeno-associated virus manufacturing processes.
First Quarter 2022 Financial Results:
Three Months Ended March 31, 2022 and 2021
Revenue: Revenue for the quarter ended March 31, 2022 consisted of $2.8 million in collaboration and service revenue recognized under our April 2021 agreements with CANbridge Care Pharma Hong Kong Limited (CANbridge) and Daiichi Sankyo Company, Limited (Daiichi Sankyo). Revenue for the quarter ended March 31, 2021 was $0.5 million consisting solely of service revenue recognized under our January 2020 agreement with Takeda Pharmaceutical Company Limited (Takeda). The agreement with Takeda expired by its own terms in the year ended December 31, 2021.
R&D Expenses: Research and development expenses for the quarter ended March 31, 2022 were $5.6 million, compared to $6.4 million for the quarter ended March 31, 2021. The decrease of approximately $0.8 million was primarily due to a decrease of $0.9 million related to LB-001 external development and manufacturing costs incurred during first quarter 2021 to start up the LB-001 SUNRISE clinical trial and manufacture appropriate clinical supply that did not re-occur during the first quarter of 2022.
G&A Expenses: General and administrative expenses were $3.6 million for the quarter ended March 31, 2022, compared to $4.1 million for the quarter ended March 31, 2021. The decrease of approximately $0.4 million was primarily driven by a decrease of approximately $0.6 million in professional service fees as we brought more professional work in-house through key hires made during 2021. As such, personnel expenses increased approximately $0.3 million as we filled key open positions within the human resources, legal and business development functions.
Net Loss: Net loss for the quarter ended March 31, 2022 was $6.7 million or $0.20 per share, compared to a net loss of $10.3 million, or $0.32 per share, for the quarter ended March 31, 2021.
Cash Position: As of March 31, 2022, we had cash and cash equivalents of $42.7 million as compared to $53.5 million as of December 31, 2021. As of March 31, 2022, we had 32,962,733 shares outstanding.
Financial Guidance: Based upon our current operating plan, we believe that our $42.7 million in cash and cash equivalents as of March 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2023.
About LogicBio Therapeutics
LogicBio® Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide®, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company's proprietary system, mAAVRx™, aims to overcome one of the current limitations of AAV manufacturing by optimizing the transfection process to improve yields and product quality. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.
About the SUNRISE Trial
The SUNRISE trial is an open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety, tolerability and preliminary efficacy of a single intravenous infusion of LB-001 in pediatric patients with methylmalonic acidemia (MMA) characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. With the aim of evaluating LB-001 at an early age, the SUNRISE trial is designed to enroll patients with ages ranging from six months to twelve years and evaluate a single administration of LB-001 at two dose levels (5 x 1013 vg/kg and 1 x 1014 vg/kg) with dose escalation subject to certain conditions.
LB-001 is an investigational, first-in-class, single-administration, genome editing therapy for early intervention in methylmalonic acidemia (MMA) using LogicBio's proprietary GeneRide® drug development platform. GeneRide technology utilizes a natural DNA repair process called homologous recombination that enables precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer. LB-001 is designed to non-disruptively insert a corrective copy of the methylmalonyl-CoA mutase (MMUT) gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver, the main site of MMUT expression and activity. LB-001 is delivered to hepatocytes intravenously via liver-targeted, engineered recombinant adeno-associated virus vector (rAAV-LK03). Preclinical studies found that LB-001 was safe and demonstrated transduction of hepatocytes, site-specific genomic integration, and transgene expression. LB-001–corrected hepatocytes in a mouse model of MMA demonstrated preferential survival and expansion (selective advantage), thus contributing to a progressive increase in hepatic MMUT expression over time. LB-001 resulted in improved growth, metabolic stability, and survival in MMA mice. The U.S. Food and Drug Administration (FDA) granted fast track designation, rare pediatric disease designation and orphan drug designation for LB-001 for the treatment of MMA. In addition, the European Medicines Agency (EMA) granted orphan drug designation for LB-001 for the treatment of MMA.
About Methylmalonic Acidemia (MMA)
Methylmalonic acidemia (MMA) is a rare and life-threatening genetic disorder affecting approximately 1 in 50,000 newborns in the United States. In the most common form of MMA, a mutation in a gene called methylmalonyl-CoA mutase (MMUT) prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no approved medical therapy addressing the underlying cause of the disease. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can require recurrent hospitalizations and cause permanent neurocognitive damage. Because of this risk for irreversible damage, early intervention is critical, and newborns are screened for MMA in every state in the United States.
Statements in this press release regarding LogicBio's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding resumption of dosing in LogicBio's SUNRISE clinical trial and timing thereof; the improvement of manufacturing yields and product quality; our expectations to continue enrollment and dosing of clinical trial subjects; our expectations on the continuation of our current collaborations; the potential of the GeneRide® platform; and the anticipated timing of announcing interim clinical data. The terms "anticipate," "progress," "expects to," "designed," "evaluate," "aim," "enables," "continue," "potential" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that we will need to obtain the approval of each clinical trial site's institutional review board prior to resuming enrollment of our SUNRISE trial; we may encounter difficulties enrolling patients; we may encounter difficulties or delays with respect to our collaborations; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators and vendors operate; manufacturing risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to develop and commercialize product candidates, including for safety, tolerability, enrollment, manufacturing or economic reasons; the timing and content of decisions made by regulatory authorities; the actual time it takes to initiate and complete preclinical and clinical studies; the competitive landscape; changes in the economic and financial conditions of LogicBio; and LogicBio's ability to obtain, maintain and enforce patent and other intellectual property protection for LB-001 and any other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in LogicBio's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and LogicBio does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.
LogicBio Therapeutics, Inc
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
Three Months Ended March 31,
Collaboration and service revenue
Research and development
General and administrative
Total operating expenses
LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE):
Total other expense, net
Net loss per share—basic and diluted
Weighted-average common stock outstanding—basic and diluted
LogicBio Therapeutics, Inc
Condensed Consolidated Balance Sheets
March 31, 2022
Cash and cash equivalents
Accounts payable, accrued expenses and other liabilities
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Berry & Company Public Relations
SOURCE LogicBio Therapeutics, Inc.